A Prospective, Randomized Controlled Trial Design To Evaluate The Effective Role Of Procalcitonin In Adopting Antibiotic Therapy In Sepsis Patients In A Tertiary Care Center
Keywords:
Sepsis, organ dysfunction, PCT, antibiotics, CRPAbstract
Background: Sepsis is a critical health challenge associated with high morbidity and mortality. Judicious use of antibiotics is highly essential to combat sepsis effectively while mitigating the rise of antimicrobial resistance. Procalcitonin (PCT), a biomarker that elevates during bacterial infections, offers the potential for adopting antibiotic therapy due to its dynamic response to treatment. This study enables to evaluate the efficacy of PCT-guided therapy in optimizing antibiotic use among sepsis patients.
Methods: This prospective, randomized controlled trial enrolled 150 patients diagnosed with sepsis based on Sepsis-3 criteria. Participants were randomized into two groups: 1)PCT-Guided Therapy Group: Antibiotic initiation and cessation guided by PCT levels.2)Standard Care Group: Antibiotic management based on clinical assessment . The primary outcome was the duration of antibiotic therapy. Secondary outcomes included clinical cure rate, length of ICU stay, 28-day mortality, and development of antibiotic resistance. Data were analyzed using appropriate statistical tests, with a p-value < 0.05 considered significant.
Results: The PCT-guided group showed a significant reduction in the duration of antibiotic therapy(7.2 vs. 10.5 days, p < 0.001) and ICU stay (10.1 ± 3.4 vs. 12.7 ± 4.1 days, p < 0.01). Clinical cure rates (88% vs. 85%, p = 0.52) and 28-day mortality (18.7% vs. 20%, p = 0.79) were comparable between groups. The incidence of antibiotic-resistant infections was lower in the PCT group (7% vs. 15%, p = 0.04). No significant adverse events were reported.
Conclusion: PCT-guided therapy effectively reduced antibiotic duration, ICU stay, and antibiotic resistance without compromising clinical outcomes, demonstrating its potential to enhance antimicrobial stewardship in sepsis management. Future studies should refine PCT algorithms and assess long-term effectiveness in diverse settings
Downloads
Metrics
References
Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. Crit Care Med. 2013;41(2):580–637. doi:10.1007/s00134-012-2769-8
Sridharan P, Chamberlain RS. The Efficacy of Procalcitonin as a Biomarker in the Management of Sepsis: Slaying Dragons or Tilting at Windmills? Surg Infect (Larchmt). 2013;14(3):187–192. doi:10.1089/sur.2012.028
Bharti AK, Verma M, Gupta A, Mishra DK. Role of procalcitonin in diagnosis of neonatal sepsis and procalcitonin guided duration of antibiotic therapy. Int J Contemp Pediatr. 2020;7(7):1690–1695. doi:10.18203/2349-3291.ijcp20203088
Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–474.
Hofer N, Zacharias E, Müller W, Resch B. An Update on the Use of C-Reactive Protein in Early-Onset Neonatal Sepsis: Current Insights and New Tasks. Neonatology. 2012;102(1):25–36. doi:10.1159/000336629
Wanner GA, Keel M, Steckholzer U, et al. Procalcitonin in Trauma and Postoperative Patients: Clinical and Experimental Studies. Shock. 2000;13(1):34–39.
Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10:CD007498. doi:10.1002/14651858.CD007498.pub3
de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomized, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819–827. doi:10.1016/S1473-3099(16)00053-0
Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. doi:10.1097/ccm.0000000000005337
Becker KL, Snider RH, Nylén E. Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations. Crit Care Med. 2008;36(3):941-952. doi:10.1097/ccm.0b013e318165babb
Kamat I, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis. 2019;69(8):1220-1229. doi:10.1093/cid/ciz545
Schüetz P, Albrich WC, Christ-Crain M, Chastre J, Müeller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther. 2010;8(5):575-587. doi:10.1586/eri.10.25
Ramilo O, Rodríguez‐Fernández R, Mejías A. Promise and Limitations of Procalcitonin to Identify Bacterial Infections in the Pediatric Intensive Care Unit. J Pediatr. 2016;176:9-10. doi:10.1016/j.jpeds.2016.09.031
Schüetz P, Albrich WC, Müeller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9:107. doi:10.1186/1741-7015-9-107
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
